论文部分内容阅读
目的探讨T2DM患者血小板膜糖蛋白Ⅵ(GPⅥ)表达水平与血管性血友病因子(vWF)的关系,分析其在T2DM合并微血管并发症中的作用。方法 262例T2DM患者根据眼底镜检查、UAER和肌电图检查分为微血管病变组和无微血管病变组。采用流式细胞仪检测GPⅥ,采用酶联免疫吸附法检测血浆vWF水平,采用逐步线性回归模型对各种微血管并发症的相关危险因素进行分析。结果 T2DM组患者GPⅥ的平均几何荧光强度(GMFI)高于正常对照(NC)组(P<0.05);微血管病变组高于无微血管病变组(P<0.05)。GPⅥ与HbA1c、UAER、vWF呈正相关(r1=0.6945,r2=0.5657,r3=0.5065,P均<0.05)。回归分析显示,GPⅥ是T2DM合并微血管病变的危险因素。结论 GPⅥ在T2DM合并微血管病变患者中表达升高,提示检测GPⅥ表达水平对预测T2DM患者合并微血管病变的风险具有一定价值。
Objective To investigate the relationship between platelet glycoprotein Ⅵ (GPVI) expression and von Willebrand factor (vWF) in T2DM patients and its role in the complication of T2DM with microvascular complications. Methods 262 cases of T2DM patients under the fundus examination, UAER and EMG were divided into microangiopathy group and no microvascular disease group. GPVI was detected by flow cytometry. Plasma vWF levels were detected by enzyme-linked immunosorbent assay (ELISA), and the risk factors of various microvascular complications were analyzed by stepwise linear regression model. Results The average geometric fluorescence intensity (GMFI) of GPVI in T2DM group was higher than that in NC group (P <0.05). The microvascular group was higher than that in non-microvascular group (P <0.05). GPVI was positively correlated with HbA1c, UAER and vWF (r1 = 0.6945, r2 = 0.5657, r3 = 0.5065, P <0.05). Regression analysis showed that GPVI was a risk factor for T2DM with microvascular disease. Conclusion The expression of GPⅥ is elevated in patients with T2DM complicated with microangiopathy, suggesting that the detection of GPVI may be of value in predicting the risk of microangiopathy in patients with T2DM.